SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-19-002966
Filing Date
2019-03-14
Accepted
2019-03-14 17:21:01
Documents
6
Period of Report
2019-04-23
Effectiveness Date
2019-03-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2019proxystatement.htm DEF 14A 685829
2 ajbackgroundpicture.jpg GRAPHIC 10605
3 cumberlandlogoa02a01.jpg GRAPHIC 12534
4 cumberlandpharmalogoa01.jpg GRAPHIC 37721
5 untitleda01a01.jpg GRAPHIC 9167
6 xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-19-002966.txt   787231
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 19681955
SIC: 2834 Pharmaceutical Preparations